Sol-Gel Technologies Ltd.

SLGL Nasdaq SEC CIK 1684693
Follow Sol-Gel Technologies Ltd. Weekly email: filings, results

Financials

Reported figures only · latest: fiscal 2025 USD · US GAAP
Revenue, last year $19.4M +68% vs prior year
Net income −$6.1M +42.1% vs prior year
EPS, diluted −$2.19 +42.2% vs prior year
Operating cash flow $322K +102.3% vs prior year
Revenue by fiscal year
$8.8M
$31.3M
$3.9M
$1.6M
$11.5M
$19.4M
FY20 FY21 FY22 FY23 FY24 FY25

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income12 fiscal years
  • Revenue
  • Net income
−$40M−$20M$0$20M$40MFY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$19.4M−$6.1M
FY24$11.5M−$10.6M
FY23$1.6M−$27.2M
FY22$3.9M−$14.9M
FY21$31.3M$3.2M
FY20$8.8M−$29.3M
FY19$22.9M−$24.6M
FY18$129K-
FY17$174K-
FY16--
FY15--
FY14--
MarginsShare of revenue
  • Operating margin
  • Net margin
−30000%−20000%−10000%0%10000%FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−38.9%−31.6%
FY24−104.1%−91.7%
FY23−1885.8%−1752.8%
FY22−418.3%−384.3%
FY219.5%10.3%
FY20−344.7%−333.9%
FY19−113.3%−107.4%
FY18−25985.3%-
FY17−18179.9%-
FY16--
FY15--
FY14--
Free cash flowOperating cash flow minus capital expenditure
−$30M−$20M−$10M$0$10MFY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25$275K
FY24−$13.9M
FY23−$17.9M
FY22−$9.7M
FY21−$7.8M
FY20−$25.7M
FY19−$23.1M
FY18−$24.5M
FY17−$26M
FY16−$18.9M
FY15−$8.3M
FY14-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Sol-Gel Technologies Ltd.
  • Healthcare median
−2000%−1500%−1000%−500%0%500%FY15FY17FY19FY21FY23FY25
Show the numbers
YearSol-Gel Technologies Ltd.Healthcare median
FY25−31.6%−30.6%
FY24−91.7%−47%
FY23−1752.8%−58%
FY22−384.3%−80.4%
FY2110.3%−71.8%
FY20−333.9%−62.2%
FY19−107.4%−46.2%
FY18-−49.6%
FY17-−45.9%
FY16-−36%
FY15-−37.8%
FY14-−35.5%